ArticleJournal of clinical microbiology2010
Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 67 citations in OpenAlex.
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Endogenous fungal endophthalmitis caused by Cladophialophora devriesii: report of a case and literature review.Journal of ophthalmic inflammation and infection · 2024Article
- Antifungal Resistance Profile of Fungal Isolates from Fungal Rhinosinusitis Patients: A Study from Tertiary Care Hospital.Journal of laboratory physicians · 2023Article
- Genome and transcriptome reveal lithophilic adaptation ofMycology · 2023Article
- Gram stain to the rescue: a case report of cerebral phaeohyphomycosis by Cladophialophora bantiana in an immunocompetent 24-year-old.BMC infectious diseases · 2022Article
- Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.Immunity, inflammation and disease · 2021Review
- Isolation and molecular characterization of clinical and environmental dematiaceous fungi and relatives from Iran.Current medical mycology · 2021Article
- A Rare Australian Case of Cutaneous Cladophialophora bantiana and Review of the Literature.Acta dermato-venereologica · 2021Review
- CNS Infections Caused by Brown-Black Fungi.Journal of fungi (Basel, Switzerland) · 2019Review
- Article
- Article
- Article
- Comparative Genomics of Sibling Species ofFrontiers in microbiology · 2017Article
- Cladophialophora bantiana osteomyelitis in a renal transplant patient.Medical mycology case reports · 2016Article
- Shared Physiological Traits of Exophiala Species in Cold-Blooded Vertebrates, as Opportunistic Black Yeasts.Mycopathologia · 2016Article
- A Rare Case of Pheohyphomycotic Lumbar Spondylodiscitis Mistreated as Koch's Spine.Case reports in orthopedics · 2016Article
- Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility.Mycopathologia · 2013Article
- Severe disseminated phaeohyphomycosis in an immunocompetent patient caused by Veronaea botryosa.Mycopathologia · 2013Article
- In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.Antimicrobial agents and chemotherapy · 2013Article
- Phaeohyphomycoses, emerging opportunistic diseases in animals.Clinical microbiology reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amplified fragment length polymorphism technique has been applied to identify neurotropic chaetothyrialean black yeasts and relatives from clinical sources. Cladophialophora bantiana, C. emmonsii, C. arxii, C. devriesii, and C. modesta, previously identified on the basis of sequencing and phenotypic and physiological criteria, were confirmed by cluster analysis, demonstrating the clear separation of C. bantiana as a rather homogeneous group from the other species. C. bantiana is a neurotropic fungus causing cerebral abscesses with a mortality of up to 70%. Successful therapy consists of neurosurgical intervention and optimal antifungal therapy. Since the latter is not clearly defined in a large series, we tested the in vitro activities of eight antifungal drugs against clinical isolates of C. bantiana (n = 37), C. modesta (n = 2), C. arxii (n = 1), C. emmonsii (n = 1), and C. devriesii (n = 1), all of which had caused invasive infections. The resulting MIC(90)s for all neurotropic C. bantiana strains were as follows, in increasing order: posaconazole, 0.125 microg/ml; itraconazole, 0.125 microg/ml; isavuconazole, 0.5 microg/ml; amphotericin B, 1 microg/ml; voriconazole, 2 microg/ml; anidulafungin, 2 microg/ml; caspofungin, 4 microg/ml; and fluconazole, 64 microg/ml. On the basis of these in vitro results and the findings of previous clinical and animal studies, posaconazole seems to be a good alternative to the standard treatment, amphotericin B, for C. bantiana cerebral infections. The new agent isavuconazole, which is also available as an intravenous preparation, has adequate activity against C. bantiana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.